| Anaplastic Large Cell Lymphoma, ALK-Positive studied in …STUDIED_INderived20 of 20show fewer |
|---|
| → studied in | NCT03113500Phase 2 · active not recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02978625Phase 2 · active not recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07729397Phase 1 · not yet recruiting Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06176690Phase 1 · recruiting Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03505554Phase 2 · completed A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05978141recruiting A Registry for People With T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07013565Phase 2 · recruiting Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04925609Phase 1/Phase 2 · recruiting Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03493451Phase 2 · completed Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01979536Phase 2 · completed Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02561273Phase 1/Phase 2 · completed Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03603847completed Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05934045unknown Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma · condition mapped ALIAS · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02419287Phase 2 · completed Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04058470Phase 1/Phase 2 · unknown Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma · condition mapped ALIAS · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04476459Phase 1/Phase 2 · unknown Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL · condition mapped ALIAS · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04796857Phase 1/Phase 2 · unknown Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL · condition mapped ALIAS · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03719898Phase 2 · withdrawn Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02729961Phase 1/Phase 2 · withdrawn Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03707847Phase 4 · unknown Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL · condition mapped ALIAS · 20 trials mapped (7 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |